Table 1 Characteristics of bsAbs used in this study

From: CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing

Description

Ab code

Clone CD3-arm

Clone HER2-arm

kD CD3 (nM)*

Apparent affinity EC50 HER2 (nM)**

kD HER2 (nM)***

bsAb CD3wt × HER2Herceptin

BisG1-huCACAO-FEAL/Herceptin-FEAR

huCACAO

Herceptin

15

5.7

0.1

bsAb CD3wt × HER2LbD2

BisG1-huCACAO-FEAL/Herceptin-FEAR LbD2

huCACAO

LbD2

15

 

100

bsAb CD3wt × HER2153

BisG1-huCACAO-FEAL/153-FEAR

huCACAO

153

15

4.2

 

bsAb CD3wt × HER2169

BisG1-huCACAO-FEAL/169-FEAR

huCACAO

169

15

6.1

 

bsAb CD3wt × ctrl

BisG1-huCACAO-FEAL/b12-FEAR

huCACAO

b12

15

N.A.

 

bsAb CD3Low × HER2Herceptin

BisG1-huCACAO-H101G-FEAL/Herceptin-FEAR

huCACAO-H101G

Herceptin

310

5.7

0.1

bsAb CD3Low × HER2LbD2

BisG1-huCACAO-H101G-FEAL/Herceptin-FEAR LbD2

huCACAO-H101G

LbD2

310

 

100

bsAb CD3Low × HER2153

BisG1-huCACAO-H101G-FEAL/153-FEAR

huCACAO-H101G

153

310

4.2

 

bsAb CD3Low × HER2169

BisG1-huCACAO-H101G-FEAL/169-FEAR

huCACAO-H101G

169

310

6.1

 

bsAb CD3Low × ctrl

BisG1-huCACAO-H101G-FEAL/b12-FEAR

huCACAO-H101G

b12

310

N.A.

 

bsAb ctrl × HER2Herceptin

BisG1-b12-FEAL/Herceptin-FEAR

b12

Herceptin

N.A.

5.7

0.1

bsAb ctrl × HER2LbD2

BisG1-b12-FEAL/Herceptin-FEAR LbD2

b12

LbD2

N.A.

 

100

bsAb ctrl × HER2153

BisG1-b12-FEAL/153-FEAR

b12

153

N.A.

4.2

 

bsAb ctrl × HER2169

BisG1-b12-FEAL/169-FEAR

b12

169

N.A.

6.1

 
  1. Wt high affinity binding to CD3, low low affinity binding to CD3, ctrl non-binding arm using HIV-1 gp120-specific mAb IgG1-b12, Herceptin interaction with HER2 at Herceptin epitope, LbD2 low affinity interaction with HER2 at Herceptin epitope due to light chain bD2 mutation, 153 high affinity interaction with membrane distal HER2 epitope “153”, 169 high affinity interaction with membrane proximal HER2 epitope “169”, N.A. not applicable, FEAL L234F, L235E, D265A Fc-inert with F405L mutations, FEAR L234F, L235E, D265A Fc-inert with K409R mutations.
  2. *kD values for WT CD3 arm described in patent WO-2017/009442 and for H101G mutant in ref. 59.
  3. **kD values for Herceptin and LbD2 mutant arms determined in ref. 60.
  4. ***Apparent affinities determined in house.